The case in front of me: ecnoglutide · four weeks · 40 °C.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
What should I decide now, and what should I defer?
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
Mechanically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
If testing multiple vials, state how many you tested and why you chose those vials.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemWorth being precise here: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 4 Mar 2026 by swab_and_wait — added the placebo-arm figures
On the detail: the practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Mechanically, acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 3 Apr 2026 by ilaria_bertone — added the method parameters
The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
Assume segregation is possible, and design your sampling to catch it if it exists.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.